Quantcast

Latest Hepatology Stories

2014-09-17 08:29:05

DUBLIN, Sept. 17, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Hepatitis C Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected such as the brain and the digestive system. Hepatitis C virus is an RNA virus belonging to the family...

2014-09-11 08:28:27

NEW YORK, Sept. 11, 2014 /PRNewswire/ -- The AASLD/EASL Special Conference on Hepatitis C will discuss new therapeutic options that can cure the vast majority of patients with HCV, insights on global epidemiology, barriers to care, and potential solutions to improve global access to therapy. Members of the media interested in attending the conference may apply for a press pass by submitting their registration request and credential information to Ann Haran at aharan@aasld.org. Join us in New...

2014-09-09 23:00:55

MarketOptimizer.org adds “Australia General Surgery Outlook to 2020” to its store. The objective is to provide information that represents the most up-to-date data of the industry possible. Dallas, Texas (PRWEB) September 10, 2014 “Australia General Surgery Outlook to 2020″, provides key market data on the Australia General Surgery Procedures. The report provides procedure volumes within market segments –     Airway Stenting Procedures...

2014-09-09 12:29:46

Argon Medical Expands its Comprehensive Biopsy Portfolio with the Addition of the TLAB® Transjugular Liver Biopsy Instrument PLANO, Texas, Sept. 9, 2014 /PRNewswire/ -- Argon Medical Devices, Inc. announced today that it has acquired Promex Technologies, LLC (d/b/a US Biopsy), a manufacturer of soft-tissue biopsy products including the TLAB® Transjugular Liver Biopsy Instrument ("TLAB"). The acquisition establishes Argon Medical as one of two companies competing in the...

2014-09-08 12:28:40

- In vivo data support potential clinical benefit of first therapeutic to target a defined subset of liver cancer patients based on genetic profile - CAMBRIDGE, Mass., Sept. 8, 2014 /PRNewswire/ -- Blueprint Medicines today announced the presentation of preclinical data investigating BLU-554, a first-in-class selective fibroblast growth factor receptor 4 (FGFR4) inhibitor, for the treatment of patients with hepatocellular carcinoma (HCC). Results demonstrate in vivo efficacy,...

2014-09-08 08:30:50

Highly Attended Celsion-Sponsored Symposium on Current Concepts for Treating Intermediate HCC included: New Paradigm in Staging HCC Patients; Phase III Studies in HCC; and Advances in Image Guided Radiofrequency Ablation LAWRENCEVILLE, N.J., Sept. 8, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced highlights from three presentations by three of the world's leading liver cancer experts and principal investigators for the Company's...

2014-09-08 08:30:26

50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months SAN ANTONIO, Sept. 8, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, presented the hepatocellular carcinoma (HCC), or liver cancer, Phase II clinical trial update for mipsagargin (G-202) at the 8(th) International Liver Cancer Association (ILCA) Conference on Saturday, September 6, 2014, in Kyoto, Japan. CEO, Craig Dionne, PhD,...

2014-09-05 23:00:54

Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone. Data Presented at International Liver Cancer Association Conference. MORRISTOWN, N.J (PRWEB) September 05, 2014 Vicus Therapeutics, an immuno-oncology company focused on bringing breakthrough immunotherapies to patients with solid-tumor cancers, announced positive results from a Phase II randomized, open-label, controlled clinical trial of its lead compound, VT-122, in combination with...

2014-09-05 08:23:08

In preclinical studies, CF102 induces hepatocyte proliferation resulting in improved liver status PETACH TIKVA, Israel, Sept. 5, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced the issuance of Patent No. 2010-529501, titled, "Method for inducing hepatocyte proliferation and uses thereof," by the Japanese Patent...

2014-09-04 08:31:36

ThermoDox® Combined with Mild Local Hyperthermia is Safe and Produces Compelling Objective Local Responses in RCW Breast Cancer Patients LAWRENCEVILLE, N.J., Sept. 4, 2014 /PRNewswire/ -- September 4, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that data from two Phase I studies on ThermoDox® in recurrent chest wall breast cancer were published in the International Journal of Hyperthermia. The article, titled "Two phase 1...


Latest Hepatology Reference Libraries

Chinese Liver Fluke, Clonorchis sinensis
2014-01-12 00:00:00

The Chinese liver fluke (Clonorchis sinensis) is a species of parasitic worm that is classified within the Platyhelminthes phylum. It can be found in Southeast Asia, Taiwan, Japan, and China and is present in nearly 30,000,000 humans today. It is thought to be one of the world’s most pervading parasites. The Chinese liver fluke requires two intermediate, or secondary, hosts and one definitive, or main, host to successfully complete its lifecycle. The first intermediate host is typically...

Southeast Asian Liver Fluke, Opisthorchis viverrini
2014-01-12 00:00:00

The Southeast Asian liver fluke (Opisthorchis viverrini) is a parasite that is classified within the Platyhelminthes phylum. It is native to Vietnam, Cambodia, Thailand, and the Lao People's Democratic Republic. It occurs in higher numbers in northern areas of Thailand when compared to central areas of Thailand, and the disease the worm causes, known as opisthorchiasis, does not occur in southern areas of Thailand. The Southeast Asian liver fluke is so small that it can only be seen under...

Echinococcus multilocularis
2014-01-12 00:00:00

Echinococcus multilocularis is a species of tapeworm that is classified within the Platyhelminthes phylum. It is one of a few worms that cause echinococcosis, a disease that affects many canid species including wolves, coyotes, foxes, jackals, domesticated dogs. Humans can also contract this disease. Adult members of this species can reach an average length of .2 inches, and like other species of tapeworm, its body is segmented by three proglottids. Its head, or scolex, is equipped with...

Liver
2013-04-30 14:18:06

The liver is the organ in charge of processing, neutralizing and excreting certain secretions for the metabolic processes. Formation and Orientation The liver is considered to be both the largest internal organ and the largest gland in the human body. It is situated just below the diaphragm, to the right of the stomach and on top of the gallbladder. There are two ways blood can travel to and from the liver: the hepatic artery and the portal vein. The hepatic artery carries blood solely...

Gallbladder
2013-03-05 14:18:48

The gall bladder is the sac-shaped organ that is the passage between the liver and intestine where bile is held. Formation and Orientation The gall bladder is relatively 8 cm by 4 cm when fully formed. The gallbladder is angled between the rectus abdominis muscle and the costal margin. It is hollow and is made up of three parts; the fundus, the body and the neck. The fundus is the part of the gallbladder that is most far from the cystic duct. This is at the same level of the...

More Articles (6 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.